Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999–2003)
Authors:
- Todd A. DaviesTDTodd A. Davies
- Y. Cheung YeeYYY. Cheung Yee
- Raul GoldschmidtRGRaul Goldschmidt
- Karen BushKBKaren Bush
- Daniel F. SahmDSDaniel F. Sahm
- Alan EvangelistaAEAlan Evangelista
Open Access
- 23 January 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 57 (3) , 437-442
Abstract
Objectives: Prevalence of single quinolone-resistance determining region (QRDR) mutations in Streptococcus pneumoniae was studied from nine institutions over 5 years to track the incidence of single QRDR mutations. Methods: All 1106 levofloxacin-susceptible pneumococci (MICs ≤2.0 mg/L) identified from 1112 total isolates (99.5% susceptibility) in TRUST 3 (1999), TRUST 5 (2001) and TRUST 7 (2003) surveillance studies from the same nine hospitals in nine states were screened for QRDR mutations. Using pyrosequencing, the strains were screened for mutations corresponding to hot spots Asp-78, Ser-79 and Asp-83 in ParC; Asp-80, Ser-81 and Glu-85 in GyrA; Asp-435 in ParE and Asp-435 in GyrB. DNA sequencing of QRDRs was performed to confirm mutations. Results: No QRDR mutations were found in any of the isolates with levofloxacin MICs ≤0.5 mg/L and no gyrA or gyrB QRDR mutations were found in any of the screened isolates (MICs ≤2 mg/L). Four single-step QRDR mutants with the following amino acid substitutions were found: ParE Asp-435 to Asn (isolated in 1999 in Colorado); ParC Asp-83 to Asn (isolated in 2001 in Kentucky); ParC Ser-79 to Phe (isolated in 2003 in Indiana) and ParC Ser-79 to Tyr (isolated in 2003 in California). These non-clonal strains had levofloxacin MICs of 1 mg/L and were non-susceptible to ciprofloxacin (MIC 2–4 mg/L). Conclusions: Overall prevalence of single QRDR mutations in levofloxacin-susceptible S. pneumoniae with MICs of ≤2 mg/L was 0.4% (4/1106) and has remained <1% within nine institutions over 5 years (1999–2003).Keywords
This publication has 34 references indexed in Scilit:
- Antimicrobial Resistance amongStreptococcus pneumoniaein the United States: Have We Begun to Turn the Corner on Resistance to Certain Antimicrobial Classes?Clinical Infectious Diseases, 2005
- The Molecular Epidemiology of Streptococcus pneumoniae with Quinolone Resistance MutationsClinical Infectious Diseases, 2005
- Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programmeJournal of Antimicrobial Chemotherapy, 2003
- Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000)Journal of Antimicrobial Chemotherapy, 2003
- Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995Antimicrobial Agents and Chemotherapy, 2002
- Prevalence of Single Mutations in Topoisomerase Type II Genes among Levofloxacin-Susceptible Clinical Strains of Streptococcus pneumoniae Isolated in the United States in 1992 to 1996 and 1999 to 2000Antimicrobial Agents and Chemotherapy, 2002
- Guidelines for the Management of Adults with Community-acquired PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Increasing Prevalence of Multidrug-ResistantStreptococcus pneumoniaein the United StatesNew England Journal of Medicine, 2000
- Practice Guidelines for the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2000
- In Vitro Activity of Newer Fluoroquinolones for Respiratory Tract Infections and Emerging Patterns of Antimicrobial Resistance: Data from the SENTRY Antimicrobial Surveillance ProgramClinical Infectious Diseases, 2000